The sequence of the Mycoplasma arthritidis superantigen, MAM: identification of functional domains and comparison with microbial superantigens and plant lectin mitogens by unknown
The Sequence  of the MFcoplasma arthritidis Superantigen, 
MAM: Identification  of Functional Domains And 
Comparison with Microbial  Superantigens 
and Plant Lectin Mitogens 
By Barry C. Cole,* Kevin L. Knudtson,*  Arnold Oliphant,r 
Allen D. Sawitzke,* Ann Pole,* Muniraj Manohar,* L. Scott Benson,* 
Elsayed Ahmed,* and Curtis L. Atking 
From the *University of Utah School of Medicine, Department of Internal Medicine, Division of 
Rheumatology; *Department of Medical Informatics; and gDepartment of Biochemistry, Salt Lake 
City, Utah, 84132 
Summary 
Mycoplasma arthritidis, an agent of chronic proliferative arthritis of rodents, secretes a potent sol- 
uble superantigen, MAM, that is active for both murine and human T  and B lymphocytes. We 
now report the complete nucleotide and amino acid sequence of MAM and show it to be dis- 
tinct from other proteins and not closely related phylogeneticaUy to other superantigens. Two 
functional domains on MAM are identified based on the ability ofpeptides encompassing these 
regions to inhibit lymphocyte proliferation by the intact MAM molecule. One  of these  do- 
mains shares short sequences or epitopes with other microbial superantigens. The second do- 
main contains the consensus legume lectin motif-B, which is important for T  cell activation by 
concanavalin (Con) A. MAM and Con A peptides containing this motif are functionally cross 
reactive, suggesting a novel secondary pathway for T  cell activation by MAM. 
S 
uperantigens are potent immunomodulatory molecules 
that are produced by a number of pathogenic bacteria 
(1, 2), endogenous murine retroviruses (3),  and may be as- 
sociated with HIV-1  (4,  5).  Superantigens  have been hy- 
pothesized to play a role in human diseases  including Ka- 
wasaki's disease, toxic shock syndrome, rheumatoid arthritis, 
and  diabetes  (6-8).  The  Mycoplasma  arthritidis  mitogen 
(MAM) ~ (9) is a particularly interesting superantigen as it is 
produced by an organism that causes spontaneous chronic 
arthritis in rodents (10).  Furthermore, evidence suggests  that 
MAM  triggers  autoimmune  arthritis  in  collagen-injected 
mice by activating the specific T  cells that drive the inflam- 
matory response (11). 
MAM is a typical superantigen in that it is presented to 
murine and human T  cells by direct binding to MHC mol- 
ecules present on accessory cell surfaces and is recognized 
by specific V~ chain segments of the TCR without MHC 
restriction (9). Although MAM is much less potent in acti- 
vating  human  T  cells  than  are  the  Staphylococcus  aureus- 
derived superantigens, unlike the latter it promotes a strong 
polyclonal B  cell activation in human PBL. This property 
suggests that MAM may be an ideal model for the study of 
1Abbreviations used in this paper: MAM,  Mycoplasma arthtitidis mitogen; 
SEA, SEB, SEC, staphylococcal  enterotoxin A, B, and C, respectively. 
the role of superantigens in the pathogenesis of human au- 
toimmune disease characterized by hypergammaglobuline- 
mia (12).  We show here that MAM  is  a  unique  protein, 
phylogenetically  distinct  from  other  superantigens,  but 
which contains cross-reactive motifs found in other T  cell 
mitogens. 
Materials and Methods 
Cloning and Sequencing of MAM.  Degenerate  oligonucleotide 
primers were designed corresponding  to the NH  2- and COOH- 
terminal  ends  of the  previously  sequenced  peptide  (13), based 
upon the codon usage ofMycoplasma capricolum (14). These prim- 
ers were  used  to  amplify,  by PCtL,  chromosomal DNA from 
M. arthritidis strain PG6. The PCIL product was labeled with 32p 
and  used  to screen  an M.  arthtitidis PG6 genomic library  con- 
structed  in  EMBL3  using  previously  described  methods  (15). 
Three clones were detected,  and  restriction  enzyme analysis of 
these  clones showed that mare was  contained within a  1.4-kbp 
XbaI fragment that  was  subcloned  into  the  plasmid  pTZ18IL 
(Pharmacia Biotech Inc., Piscataway, NJ) and sequenced  by use 
of the Sanger dideoxy chain termination method (15). 
Analysis of Physical Properties Of MAM.  The algorithms of Gar- 
nier et al. (16) and Chou and Fasman (17) were used to predict 
the  secondary  structure  for  MAM.  Hopp  and  Wood's  (18) 
method predicted  hydrophilicity  values. Secondary structure  and 
hydrophilicity  analyses were performed using the DNASIS v. 2.0 
(Hitachi Software, San Bruno, CA) sequence analysis software. 
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BALB/c splenocytes  was measured in a microtiter plate  assay at 
72 h after a 24 h pulse with [3H]TdR as detailed previously (19). 
For blocking, MAM peptides  at  0.25-1  mg/ml were incubated 
with lymphocytes for 1 h at 37~  before addition of a 1:20,000 
dilution (approximately  ~<50 pg/ml) of pure MAM in complete 
RPMI  1640  medium.  Due  to insolubility,  peptide  10 was  not 
tested. To determine whether the inhibitory peptides  were toxic, 
they were incubated at the above concentrations with a B  cell 
lymphoma (2PK-3), two T cell hybridomas (one MAM reactive, 
V~38.2, and one MAM nonreactive, V~3) and L929 fibroblasts in a 
28-h assay using an 8-h pulse with [3H]TdR. Peptides  and nucle- 
otides were synthesized  by the University of Utah DNA/Amino 
Acid Core Facility.  Peptides  based on the MAM sequence were 
as follows: peptide 1, amino acids 1-17; 2A, 15-31; 2B, 11-38; 3, 
33-57; 4, 51-74; 5, 71-95; 6, 89-118; 7, 112-142; 8, 136-164; 
9, 160-180; 10, 173-195; and ll,  189-213. 
VI3 Usage by Native and Recombinant MAM.  V~ usage by MAM 
and other control superantigens  was measured by IL-2 produc- 
tion by specific V~ TCR-bearing T  hybridomas in the presence 
of ",/-irradiated 2PK-3 AC  (both at  10  s cells/ml).  Vol  (KSEA), 
V~3 (5KC),  and V~11 (1BVBll-17.7)  were kindly provided by 
Dr. P.  Marrack (National Jewish Center,  Denver, CO), V136 by 
Dr. B Huber (Tufts  University, Boston, MA), and Vf38.2 (2Hd- 
11.2) by Dr. B. Araneo (University of Utah, Salt Lake City, UT). 
Methods have been described  (20). Staphylococcus  enterotoxins 
A  and B  (SEA,  SEB) were  obtained from Toxin Technology, 
Inc.  (Sarasota,  FL)  and  Con A  from Sigma  Chemical  Co.  (St. 
Louis, MO). 
Sequence Analysis.  Superantigen  amino  acid  sequences  were 
obtained from the current PIP. and Swiss-protein databases, from 
ho et al. (21), and our sequence data for MAM. All were aligned 
using the ClustalV  algorithm (D.  Higgins, European Molecular 
Biology Laboratory)  using  default  settings.  The  DDMATKIX 
application  of the IntelliGenetics  (IntelliGenetics,  Inc., Mountain 
View, CA) package was used to search  for regions of homology 
between  MAM  and  other  superantigens/mitogens  using  the 
Jimenez-Montano similarity  alphabet  for amino acid  homology. 
A search for moti8 in MAM was conducted using the Motifs pro- 
gram in the GCG sequence analysis software  package (Madison, 
WI). Aligned sequences  were examined using an heuristic  search 
in PAUP 3.0 (David  Swofford, Illinois National History Survey, 
Champaign, IL), and the best-fit  unrooted dendogram was saved. 
Results and Discussion 
Previously, MAM was purified to homogeneity, and the 
sequence of the first 53 amino acids of the mature protein 
was  obtained  by Edman  degradation  (13).  This  sequence 
was  used  to  design  primers  to  generate  a  PCR  product 
probe for screening of an M.  arthritidis genomic library.  It 
should be  noted  that  the  PCR  product,  when  sequenced 
and  translated,  gave  the  amino  acid  sequence  previously 
obtained  by  Edman  degradation.  The  probe  identified 
three EMBL3  clones containing mam.  The gene was sub- 
cloned, and the nucleic acid sequence was determined (Fig. 
1). The nucleic acid sequence was translated in the reading 
frame  giving  the  amino  acid  sequence  previously  deter- 
mined by Edman degradation.  MAM begins with the me- 
thionine  codon at  nucleotide  127  and  ends  at  nucleotide 
766.  A  p-independent  transcriptional  termination  region 
was  predicted  using  the  Termination  program  contained 
within  the  GCG sequence  analysis software package.  The 
three  UGA universal  stop  codons at  amino  acid positions 
132,  177,  and  178 were read as  tryptophans based on the 
codon usage for the Mycoplasmatales  (14).  After converting 
these  stop  codons  to  UGG  tryptophan  codons,  the  full- 
length, mature MAM protein encoded by nucleotides 127- 
766 was expressed in Escherichia coli and purified by methods 
to  be  described  (Knudtson,  K.L.,  M.  Manohar,  and  B.C. 
Cole, manuscript in preparation).  This recombinant protein 
(rMAM)  was  biologically  similar  to  native  MAM  and 
showed an identical VI3 usage that was distinct from that of 
other superantigens  (Table  1). 
MAM was predicted to be a protein of 213 amino acids 
with a calculated molecular weight of 25,193. This is simi- 
lar to the values reported for the staphylococcal and strep- 
tococcal superantigens  (6).  However,  the  calculated  pI of 
10.1  makes  MAiM  the  most basic  of the  known  bacterial 
superantigens.  The MAM sequence  does not contain cys- 
teine  residues,  and  so  the  disulfide  bond,  present  in most 
1  -23 
rbs  M  K  T 
GC  TGTGAAAATGAAATTC  TTC  AC  AAAT  TT  AAAAATCATAAGGAATAAAAAAATGAAAAC  A 
61  -3 
K  K  L  L  I  A  T  V  T  L  A  T  G  L  L  G  I  L  P  L 
AAAAAATTATTAATCGCAACCGTCACTTTAGCGACTGGGCTTTTAGGAATTTTACCATTA 
121  ~I  18 
T  S  M  K  L  R  V  E  N  P  K  K  A  Q  K  H  F  V  Q  N 
AC  TAGCATGAAACTTAGAGTTGAAAATC  CTAAAAAAGC  TCAAAAGCAT  TTTGT  GCAAAAT 
181  38 
L  N  N  V  V  F  T  N  K  E  L  E  D  I  Y  N  L  S  N  K 
TTAAATAATGT  TG  TATTTACTAATAAAGAGCTTGAAGATATC  TACAATTTAAG  TAATAAA 
241  58 
E  E  T  K  E  V  L  K  L  F  K  L  K  V  N  Q  F  Y  R  H 
GAAGAAACAAAAGAAGTATTAAAATTGTTTAAATTGAAGGTCAACCAATTTTATAGACAT 
301  78 
A  F  G  I  V  N  D  Y  N  G  L  L  E  Y  K  E  I  F  N  M 
GCTTTTGGTATAGTGAATGACTACAATGGACTTCTTGAATACAAAGAAATTTTTAATATG 
361  98 
M  F  L  K  L  S  V  V  F  D  T  Q  R  K  E  A  N  N  V  E 
ATGTTTTTAAAATTAAGCGTTGTCTTTGACACACAACGTAAAGAGGCAAATAACGTCGAA 
421  118 
Q  I  K  R  N  I  A  I  L  D  E  I  M  A  K  A  D  N  D  L 
CAAATCAAAAGAAATATCGCTATTTTAGATGAAATAATGGCAAAAGC  AGATAACGATTTA 
481  138 
S  Y  F  I  S  Q  N  K  N  F  Q  E  L  W  D  K  A  V  K  L 
TCTTACTTTATATCTCAGAATAAGAATTTTCAAGAGTTATGAGATAAAGCTGTCAAACTA 
541  158 
T  K  E  M  K  I  K  L  K  G  Q  K  L  D  L  R  D  G  E  V 
ACTAAAGAAATGAAAATAAAACTTAAAGGCCAAAAACTAGATCTTCGTGATGGTGAAGTT 
601  178 
A  I  N  K  V  R  E  L  F  G  S  D  K  N  V  K  E  L  W  W 
GCAATAAACAAAGTAAGAGAATTATTTGGCAGCGACAAAAATGTAAAAGAGCTTTGATGA 
661  198 
F  R  S  L  L  V  K  G  V  Y  L  I  K  R  Y  Y  E  G  D  I 
TTTAGATCTCTTCTAGTAAAAGGTGTTTACCTTATAAAACGCTATTACGAAGGTGATATT 
721  213 
E  L  K  T  T  S  D  F  A  K  A  V  F  E  D  *** 
GAACTTAAAACGACATCGGATTTTGCAAAAGCTGTTTTTGAAGATTAATATTAAACATAT 
781 
AT  AAC  AAAT  TATCC  CC  C  CAAT~GTTGGGGGGAT  TTTAAATAAATT  C  CTTGC  ATC 
Figure 1.  Nucleotide  and derived amino acid sequence of the MAM 
gene (mare). The nucleotide positions are numbered on the left and the 
amino acid positions on  the right. The  double underline denotes the 
probable ribosomal binding site (rbs). The single arrows indicate an inverted 
repeat representing the predicted transcriptional termination region. The 
single underline indicates the complementary  bases within the inverted re- 
peat. The asterisks represent the translational stop codon for MAM. This se- 
quence will appear in the GenBank under the accession number U33151. 
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IL-2 (U/ml) produced by T hybfidomas +  APC 
Inducer*  VIM  V133  V138.2  V1311  Vl36 
None  0  0  0  0  0 
MAM  0  0  232  0  640 
rMAM  0  0  428  0  612 
SEA  691  1,883  0  1,181  NT* 
SEB  0  1,832  608  0  0 
Con A  310  2,240  315  2,560  539 
"Native MAM and recombinant MAM (rMAM) were tested at ~  ~50 
ng/ml,  SEA and SEB at 5 t~g/ml, and Con A at 15 I*g/ml. 
*Not tested. 
other superantigens, cannot be formed. Since MAIM is a se- 
creted product (9), we sought evidence of a signal peptide. 
Upstream of the mature protein start site there is encoded a 
25-amino acid peptide that possesses most of the character- 
istics  that  define  bacterial  signal  peptides  (22)  (Fig.  1). 
Moreover, just  further  upstream  is  a  potential  ribosomal 
binding site,  the  sequence  of which complements the  3'- 
OH end of the 16S rRNA ofM. arthritidis  (23). 
Previously,  it  was  reported  that  culture  supernatants 
from 32 strains of M.  arthritidis  all possessed mitogenic ac- 
tivity  (13).  The presence  of the  mare gene in these strains 
was  confirmed by the  ability  of primers  to  the  5'  and  3' 
ends  of the  gene  to  generate  the  appropriate  "-%50-bp 
product by PC1L (data not shown).  The presence  of mare 
or mam-like genes in other Mycoplasma species was examined 
by DNA-DNA  hybridization using  mam  as  a  probe.  Ge- 
nomic DNA from human mycoplasmas including M. pneu- 
moniae,  M.  hominis,  M. penetrans,  M. fermentans,  M.  salivaro 
ium, M. orale, and M. buccale  failed to hybridize with the mam 
probe,  even under conditions  of low stringency  (data not 
shown). Thus, mam may occur only in M.  arthritidis. 
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Figure  2.  Prediction of the  hydrophilcity profile  of MAM. The 
method of  Hopp and Woods (18) was used. The 11 overlapping  synthetic 
peptides are illustrated at the bottom. 
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Figure 3.  Inhibition  of MAM-induced lymphocyte proliferation by a 
panel of MAM peptides. The results are  expressed as the  percent of 
[3H]TdK uptake by MAM in the presence of peptide versus the uptake 
seen with MAM alone; the mean of  three detenmnations -+ SD is shown. 
MAM  and  its  gene  were  found  to  be  unique  because 
protein and gene database searches failed to identify similar 
sequences.  The 27%  G  +  C  content of mam is  consistent 
with  that  of most mycoplasma genomes  (14),  but  is  also 
similar to that of the staphylococcal and streptococcal toxin 
genes.  Considering  a  common origin for these  genes,  we 
conducted  a  phylogenetic  analysis  comparing  the  amino 
acid  sequences  of MAM  and  other  superantigens.  MAM 
was not closely related to other superantigens and alone oc- 
cupied one of three main branches on an unrooted phylo- 
gram (not shown). The closest similarity was between MAM 
and streptococcal pep M5 (24) at 24% sequence similarity. 
To identify active domains on MAM, a series of overlap- 
ping MAM peptides  were  synthesized  (Fig.  2)  and  tested 
for their ability to inhibit lymphocyte proliferation by na- 
tive MAM (Fig.  3). Two candidate functional domains were 
identified. The first, represented in peptides 2A (MAMls_31) 
and 2B  (MAM11_38)  inhibited  MAM-induced proliferation 
in a dose-dependent manner (Fig. 3), but had no effect on 
proliferation induced by Con A, indicating that MAM pep- 
tide 2 was not toxic (data not shown). The second, peptide 
5  (MAM71_95) also blocked MAM activity (Fig. 3), but also 
inhibited proliferation induced by Con A  by 50%  (Fig. 4). 
The  inhibition  by MAM71_9s  was  not  due  to  toxicity,  as 
subsequent addition of Con A  restored the proliferative re- 
sponses to the values obtained with Con A  alone  (Fig.  4). 
In  addition,  neither  MAMas_31  nor  MAM71_95 suppressed 
the  growth of B  or T  hybridomas or L929 cells  (data not 
shown). 
Although MAM was not closely related to other super- 
antigens, searches for common sequences revealed that sev- 
eral superantigens  shared potential epitopes with the func- 
tional MAM peptide 2  (Fig.  5 A). Potential epitopes were 
defined  to  contain  at least  four adjacent  identical  or con- 
served amino acids followed by additional  shared  residues 
separated from the former by no more than three dissimilar 
residues. Two overlapping alignments of SEB with MAM  11-38 
are shown. The SEB region that interacts with MHC  mol- 
ecules  comprises a  hydrophobic area  that includes  impor- 
tant residues at SEBa4 ' 45, 47 (25).  This is followed by a hy- 
drophilic  or  polar  region  containing  SEB67  that  is  also 
1107  Cole et al. Figure  4.  Peptide-mediated blocking of lymphocyte proliferation in 
response to Con A and MAM. MAMvl_gs  and Con A2_16  peptides were 
tested at 0.125-1 mg/ml for ability to block lymphocyte proliferation to 
MAM at 1:20,000 (~<50 pg/ml) or Con A at 5 ~g/ml. 
important  for  MHC  binding  (26)  and  which  is  situated 
within  the shared MAM epitope.  As is apparent from Fig. 
2, the MAM peptide  2  has a similar profile, with a hydro- 
phobic area followed by one of hydrophilicity, which lies 
in  a  predicted  [3  sheet.  The  region  of similarity  between 
MAM12_29  and  the  conserved  retroviral  sequence  of the 
murine  mammary  tumor  virus  7  (MMTV-7s0_99)  (27)  is 
noteworthy since a similar retroviral peptide bound to MHC 
molecules  and  competitively blocked the  binding  of SEA 
to the  same MHC  molecules  (28).  Regions similar  to the 
retroviral sequence were also present in the SEC superanti- 
gens  (residues  127-139)  (29)  and in streptococcal pep M5 
toxin (residues  101-112)  (24), although there is no data to 
suggest that these sequences play a role in the activity of these 
latter superantigens.  A  sequence similarity to MAM16.2,  3 was 
also  present  in  the  HIV-1  gp160  envelope  glycoprotein, 
which  has  recently  been  shown  to  exhibit  superantigen- 
like  properties  (5)  and  which  selectively  expands  T  cells 
bearing those V~ chain segments that are used by MAM (5, 
30). Regions of similarity between pep M5 and other bac- 
terial superantigens have also been noted (24). 
Whereas  few  sequence  similarities  were  seen  between 
MAM peptide  5  and other superantigens,  a search for mo- 
tifs revealed the striking result that MAM, but not other su- 
perantigens, contained the seven-residue lectin legume motif 
[5 consensus sequence present in all legume lectins includ- 
ing Con A. Shown in Fig. 5 B is the consensus legume lec- 
tin motif [3, the Con A2_16 and MAM71_9s peptides, and the 
motif (shaded) that  they  contain.  Peptide  Con  A2-16 con- 
taining this  motif strongly inhibited  Con A-induced lym- 
phocyte proliferation  (Fig.  4)  as  well  as  that  mediated  by 
Figure  5.  Sequence  comparisons between ac- 
tive MAM peptides and other mitogens. (A) Re- 
gions shared by MAM peptides 2A and 2B and 
other  microbial superantigens. Identical or con- 
served residues are blocked. Shaded residues fall 
within potential epitopes. (B) Comparison of the 
legume lectin motif ~ present in MAM peptide 5 
(MAM71_gs) and Con A2_16. Numbering of Con A 
residues  is  according to  Sharon and  Liss (31), 
Metal-binding sites on Con A are marked with an 
asterisk. 
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for T  cell activation. At high concentrations, Con A2-16 also 
significantly inhibited MAM-induced proliferation (Fig. 4). 
Peptide MAM71.gs  strongly inhibited MAM-induced lym- 
phocyte activation and partially inhibited that mediated by 
Con A. Thus the Con A peptide and MAM peptide 5 ap- 
pear to be functionally cross-reactive. Metal-binding sites 
within  and just downstream of the legume lectin motif 13 
(see Fig.  5/3) are important in achieving the saccharide bio- 
active conformation (31, 32). It is interesting that the motifs 
in MAM (Fig. 5 B) and Con A are both associated with hy- 
drophobic  regions  (Fig.  2)  of their  respective molecules. 
This suggests that in MAM  the motif may serve a similar 
function by stabilizing the bioactive form of the molecule 
and/or by configuring a site that interacts with a surface lym- 
phocyte receptor. 
In conclusion, MAM is not phylogenetically or structur- 
ally closely related to other superantigens on the basis of its 
linear sequence and a preliminary analysis of its predicted 
secondary structure.  Thus, MAM is the first representative 
of a new class of superantigen. Despite these major differ- 
ences, we have presented evidence that short regions of se- 
quence homology may predict functional domains that are 
common to several superantigens. The domains so identified 
require  confirmation of cross-reactive function.  The pres- 
ence of the legume lectin motif in MAM may indicate that 
this  superantigen  alone  exhibits  a  unique  interaction  site 
that contributes to lymphocyte activation. Analysis of the 
x-ray crystallographic structure of MAM and of a library of 
deletion mutants are now required to more precisely define 
the molecular interactions that lead to T  and B  cell super- 
antigenic activity. 
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